ArticleHospital pharmacy2021
Fluoxetine in the Management of Major Depressive Disorder in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials.
Article in Hospital pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Effectiveness of interventions for anxiety and depression in children and young people: an umbrella review of meta-analyses.European child & adolescent psychiatry · 2026Pooled it
- Population-Based Trends in Antidepressant Dispensing Among Children and Adolescents in Manitoba, Canada.Pharmacoepidemiology and drug safety · 2026Article
- Antidepressant use in German adolescents with a first recorded diagnosis of depression: a retrospective cohort study.European child & adolescent psychiatry · 2026Article
- Efficacy and Safety of Escitalopram for Major Depressive Disorder in Children and Adolescents: A Systematic Review and Meta-Analysis with Age-Specific Findings.Neuropsychiatric disease and treatment · 2026Review
- Fluoxetine Use for Very Young Children with Major Depression Disorder: A Pilot Randomized Clinical Trial.Advanced biomedical research · 2026Article
- Curcumin Ameliorates Depressive-like Behaviors by Modulating mGluR2/PGC-1α-Mediated Glutamatergic Homeostasis and Mitochondrial Function.Molecular neurobiology · 2025Article
- Neural oscillations in the nucleus accumbens-dorsal hippocampal circuits and behavioral effects of acute fluoxetine administration during the Tail suspension test in mice.Experimental brain research · 2025Article
- Negative efficacy of antidepressants in pharmacotherapy of child and adolescent depression.World journal of psychiatry · 2025Review
- Prevalence of Antidepressant Prescription in Adolescents Newly Diagnosed with Depression in Germany.Children (Basel, Switzerland) · 2024Article
- Research Progress on the Pharmacodynamic Mechanisms of Sini Powder against Depression from the Perspective of the Central Nervous System.Medicina (Kaunas, Lithuania) · 2023Review
- The Possible Ameliorating Role of Fisetin on Hepatic Changes Induced by Fluoxetine in Adult Male Albino Rats: Histological, Immunohistochemical, and Biochemical Study.Journal of microscopy and ultrastructureArticle
- Metabolomic identification of biochemical changes induced by fluoxetine in an insulinoma cell line (MIN6).Research in pharmaceutical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFluoxetine is a serotonin-specific reuptake inhibitor antidepressant and is the only approved pharmacological treatment for major depressive disorder (MDD) in children and adolescent.
methodsWe searched the published randomized controlled-trials to review fluoxetine efficacy and tolerability using the databases PubMed, EudraCT, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials for fluoxetine role in managing MDD in children and adolescents. A meta-analysis was conducted using the identified 7 clinical trials to assess efficacy using the outcomes: Children's Depression Rating Scale-Revised (CDRS-R), Clinical Global Impressions-Severity of Illness (CGI-S) and Clinical Global Impressions-Improvement (CGI-I) response rate. The risk of discontinuation due to adverse effects and common side effects were examined.
resultsThe mean difference in change from baseline for CDRS-R was -2.72 (95% confidence interval [CI], -3.96, -1.48) favoring fluoxetine treatment (
conclusionFluoxetine demonstrates significant improvements in symptom intensity control in young patients suffering from MDD and is considered well tolerated with similar rates of trials discontinuation; however, fluoxetine was associated with a higher risk of headache and rash side effects. These findings will guide psychiatrists and pharmacists in their clinical role for supporting the care of young mental health patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.